Physician profile
Dana Kang
NPI 1982803813
$9,245.35
in general payments reported to CMS, 2019-2025
33 companies · $1,775 in 2025
The $1,775 reported for 2025 was more than what 93% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $698 · 2020: $251 · 2021: $893 · 2022: $1,261 · 2023: $2,022 · 2024: $2,344 · 2025: $1,775.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,142.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,141.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,612.09 | 2019-2025 | |
| Incyte Corporation | $1,033.23 | 2021-2025 | Opzelura |
| Genzyme Corporation | $1,006.87 | 2021-2025 | |
| Leo Pharma INC. | $760.95 | 2019-2025 | Adbry, Anzupgo |
| Regeneron Healthcare Solutions, INC. | $741.35 | 2020-2025 | Dupixent, Libtayo |
| Janssen Biotech, INC. | $545.17 | 2021-2025 | Tremfya |
| Sun Pharmaceutical Industries INC. | $540.45 | 2020-2025 | Ilumya, Absorica Ld, Winlevi |
| Pfizer INC. | $464.89 | 2019-2025 | |
| Lilly USA, LLC | $444.74 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Galderma Laboratories, L.P. | $285.73 | 2019-2025 | Nemluvio |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $259.45 | 2019-2025 | Cabtreo, Siliq, Jublia |
| Almirall LLC | $182.78 | 2019-2024 | Klisyri, Seysara |
| E.R. Squibb & Sons, L.L.C. | $174.20 | 2023-2025 | Sotyktu |
| Novartis Pharmaceuticals Corporation | $168.81 | 2019-2025 | |
| Biofrontera INC. | $164.10 | 2019-2025 | Ameluz, Xepi, Bf-Rhodoled |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $120.90 | 2023-2025 | Zoryve |
| Epi Health, LLC | $102.29 | 2019-2022 | |
| Amgen INC. | $92.96 | 2022-2025 | Otezla, Otezla |
| Stemline Therapeutics INC. | $83.33 | 2021 | |
| Mayne Pharma Commercial LLC | $64.80 | 2019-2024 | |
| Revance Therapeutics, INC. | $48.98 | 2024 | Daxxify |
| Strata Skin Sciences, INC. | $45.53 | 2019-2025 | Xtrac |
| Prugen, INC. Pharmaceuticals | $42.28 | 2019 | |
| Aclaris Therapeutics, INC. | $35.48 | 2019 | |
| Allergan, INC. | $33.25 | 2020-2022 | |
| Helsinn Therapeutics (U.S.), INC. | $31.56 | 2023-2024 | Valchlor |
| Fresenius Kabi USA, LLC | $30.67 | 2023 | Idacio |
| Ucb, INC. | $27.01 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.05 | 2024 | Spevigo |
| Taro Pharmaceuticals USA, INC. | $23.99 | 2019 | |
| Botanix Sb INC | $19.18 | 2025 | Sofdra |
| Mission Pharmacal Company | $16.91 | 2019 | |
| Journey Medical Corporation | $16.37 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dana Kang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.